Anterior|Siguiente

Progreso en la investigación de sustancias farmacológicamente activas y mecanismos de acción de Xinglou Chengqi Tang en el tratamiento de las complicaciones del accidente cerebrovascular

  • role： First author第一作者
  • Affiliation：

    School of Basic Medical Sciences， Hengyang Medical College， University of South China，Hengyang 421001， China

  • Email：694564934@qq.com
  • Introduction：张育谨，从事中药神经药理学研究，E-mail：694564934@qq.com
ZHANG Yujin1,  
  • Affiliation：

    School of Basic Medical Sciences， Hengyang Medical College， University of South China，Hengyang 421001， China

LIU Xiangzhuo1,  
  • Affiliation：

    School of Basic Medical Sciences， Hengyang Medical College， University of South China，Hengyang 421001， China

CHEN Zhouyang1,  
  • Affiliation：

    School of Basic Medical Sciences， Hengyang Medical College， University of South China，Hengyang 421001， China

SONG Zihao1,  
  • Affiliation：

    School of Basic Medical Sciences， Hengyang Medical College， University of South China，Hengyang 421001， China

LIU Xinyi1,  
  • Affiliation：

    School of Basic Medical Sciences， Hengyang Medical College， University of South China，Hengyang 421001， China

YAN Yizhi1,  
  • Affiliation：

    Chenzhou No．1 People's Hospital，Chenzhou 423000， China

LI Chaoya2,  
  • Affiliation：

    Hubei Key Laboratory for Kidney Disease Pathogenesis and Intervention， Hubei Polytechnic University School of Medicine，Huangshi 435003， China

FANG Yingyan3,  
  • Affiliation：

    School of Basic Medical Sciences， Hengyang Medical College， University of South China，Hengyang 421001， China

YANG Shasha1,  
  • Affiliation：

    School of Basic Medical Sciences， Hengyang Medical College， University of South China，Hengyang 421001， China

CHENG Xueqin1,  
  • Affiliation：

    School of Basic Medical Sciences， Hengyang Medical College， University of South China，Hengyang 421001， China

XIE Zhou1,  
  • Affiliation：

    School of Basic Medical Sciences， Hengyang Medical College， University of South China，Hengyang 421001， China

TAN Sijie1,  
  • role： Corresponding author通信作者
  • Affiliation：

    School of Basic Medical Sciences， Hengyang Medical College， University of South China，Hengyang 421001， China

  • Email：zengp@usc.edu.cn
  • Introduction：曾鹏，博士，教授，从事中药神经药理学研究，E-mail：zengp@usc.edu.cn； *
ZENG Peng1*,  
  • role： Corresponding author通信作者
  • Affiliation：

    School of Basic Medical Sciences， Hengyang Medical College， University of South China，Hengyang 421001， China

  • Email：2021000048@usc.edu.cn
  • Introduction：张月，博士，讲师，从事中药药理学研究，E-mail：2021000048@usc.edu.cn
ZHANG Yue1*

resumen

El accidente cerebrovascular es la principal causa de muerte y discapacidad en adultos en nuestro país. Sus complicaciones comunes incluyen anomalías en el sistema digestivo, deterioro cognitivo, depresión, neumonía asociada al accidente cerebrovascular y hemiplejía. El tratamiento combinado de la medicina china y occidental para el accidente cerebrovascular y sus complicaciones tiene un gran potencial. Xinglou Chengqi Tang es una fórmula representativa del tratamiento "de arriba hacia abajo" del accidente cerebrovascular, con eficacia demostrada y alta seguridad. Clínicamente, Xinglou Chengqi Tang se usa comúnmente para tratar el accidente cerebrovascular y sus complicaciones, pero la cantidad y calidad de los ensayos clínicos necesitan mejorar, y la investigación básica es débil, con componentes activos desconocidos y mecanismos de acción con múltiples objetivos poco claros. Este artículo revisa la base farmacológica, la evaluación de la fabricación y seguridad, la investigación clínica y el progreso en el estudio de los mecanismos de acción de Xinglou Chengqi Tang en el tratamiento de las complicaciones del accidente cerebrovascular. El artículo resume 22 ingredientes activos clave de Xinglou Chengqi Tang para tratar el accidente cerebrovascular agudo con síndrome de humedad y calor en las vísceras, incluyendo resveratrol, quercetina, luteolina, campferol, apigenina, (+)-catequina y adenosina, que tienen buenas propiedades farmacocinéticas y alta biodisponibilidad. El mecanismo de acción de Xinglou Chengqi Tang en el tratamiento de las complicaciones del accidente cerebrovascular es complejo e incluye la respuesta inflamatoria, el eje cerebro-intestino, el eje hipotálamo-hipófisis-adrenal (eje HPA), el microbioma intestinal, factores neurotróficos, autofagia celular, estrés oxidativo y daño por radicales libres. Este artículo ayuda a profundizar la comprensión de la base farmacológica y los mecanismos de acción de Xinglou Chengqi Tang en el tratamiento de las complicaciones del accidente cerebrovascular, proporcionando una base teórica para la aplicación clínica y el desarrollo de fármacos contra las complicaciones del accidente cerebrovascular.

palabra clave

medicina tradicional china; Xinglou Chengqi Tang; complicaciones del accidente cerebrovascular; base farmacológica; mecanismo de acción

References

  1. 1.
    Group Report On Stroke Center.Brief report on stroke center in China，2022［J］.Chin J Cerebrovasc Dis，2024，21（8）：565-576.
  2. 2.
    YIN J，YANG Y F，YUN Y D，et al.Research progress on regulating the microbiome-gut-brain axis with traditional Chinese medicine to intervene in post-stroke depression［J］.Chin Med Nat Prod，2024，doi：.
  3. 3.
    ZENG Y H，YUAN J H，PANG J X，et al.Effects of wheat-grain sized cone moxibustion plus scalp points with sustained needle retaining on the cognitive function and serum markers in non-dementia cognitive impairment in the recovery stage of cerebral stroke［J］.Shanghai J Acupunct Moxibust，2024，43（7）：730-733.
  4. 4.
    LI W J，LI Y，ZHANG J，et al.Application of sleep nursing intervention in patients with post-stroke sleep disorders［J］.Chin J Stroke，2024，19（7）：864.
  5. 5.
    JI T Y.A case study on the treatment of patients with post-stroke dysphagia by the Zi-Mu tonic-diarrhea method［D］.Nanjing：Nanjing University of Chinese Medicine，2022.
  6. 6.
    SUI R R，SHAN Y Z，ZHAO X J，et al.Advances in the correlation between gut microbiota and post-stroke pneumonia［J］.Chin J Stroke，2023，18（8）：947-951.
  7. 7.
    LUO Y，DU X，YIN K J，et al.Acupuncture treatment of hemiplegia after stroke based on the theory of "sanjiao-original yang"［J］.J Tradit Chin Med，2024，65（17）：1825-1828.
  8. 8.
    LIU R R，SONG J Y，XI Y S.Research progress on constipation after stroke［J］.Chin J Gen Pract Nurs，2024，22（8）：1443-1446.
  9. 9.
    ZHANG X L，YANG Q G，ZHAO J M，et al.Study on the clinical effect of acupuncture on constipation after stroke in middle-aged and elderly people by "regulating the meridians and the viscera"［J］.Lishizhen Med Mater Med Res，2024，35（7）：1667-1669.
  10. 10.
    LI Z S，BAI W，LI T，et al.Effect of "Chifeng Yingyuan" acupuncture technique in treating post-stroke hemiplegia［J］.Shaanxi J Tradit Chin Med，2024，45（9）：1270-1273.
  11. 11.
    LU Y M，XU N，LU Y，et al.Effectiveness of timely Anshen foot bath combined with auricular acupressure treatment on post-stroke insomnia［J］.Hebei J Tradit Chin Med，2024，46（6）：996-999.
  12. 12.
    ZHANG Z Q，ZHENG L Q，SUN C M.Review of advances in traditional Chinese medicine for acute cerebral infarction［J］.China Mod Med，2022，29（12）：34-38.
  13. 13.
    YU Z M.Academician WANG Yongyan's experience in treating stroke［C］//China Association of Chinese Medicine，Zhang Zhongjing Theory Branch.Proceedings of the 20th national academic annual conference on ZHANG Zhongjing's theory，institute of basic theory for Chinese medicine，China Academy of Chinese Medical Sciences，2012.
  14. 14.
    YU Z M，WANG Y Y.Stroke "top-down treatment"［J］.Chin J Basic Med Tradit Chin Med，2010，16（1）：6-7.
  15. 15.
    XIONG L L，LIU Y X，WANG S H，et al.Meta-analysis of Chengqi decoction in treating constipation after stroke［J］.J Pract Tradit Chin Intern Med，2021，35（5）：110-113.
  16. 16.
    ZENG P，WANG X M，SU H F，et al.Protective effects of Da-cheng-qi decoction in rats with intracerebral hemorrhage［J］.Phytomedicine，2021，90：153630.
  17. 17.
    ZHANG T，YANG C，CHU J，et al.Emodin prevented depression in chronic unpredicted mild stress-exposed rats by targeting miR-139-5p/5-lipoxygenase［J］.Front Cell Dev Biol，2021，9：696619.
  18. 18.
    ZHANG T.Brain proteomics study and emodin intervention of young male depressed rats after CUMS exposure［D］.Wuhan：Huazhong University of Science & Technology，2017.
  19. 19.
    ZENG P，SHI Y，WANG X M，et al.Emodin rescued hyperhomocysteinemia-induced dementia and Alzheimer's disease-like features in rats［J］.Int J Neuropsychopharmacol，2019，22（1）：57-70.
  20. 20.
    WANG S，WU D，ZHANG J B，et al.Research progress of Xinglou Chengqi decoction in treatment of stroke with heat-phlegm and sthenic-fu syndrome［J］.Chin J Exp Tradit Med Form，2021，27（10）：213-221.
  21. 21.
    CHEN P，JIANG L，GENG H，et al.Effectiveness of Xinglou Chengqi decoction on constipation in patients with acute ischemic stroke： A randomized controlled trial［J］.J Tradit Chin Med，2020，40（1）：112-120.
  22. 22.
    CHEN S X，CHENG Y S，LIN C Y，et al.Clinical efficacy of Xinglou Chengqi decoction in treatment of cognitive impairment after ischemic stroke with phlegm-heat and bowel-repletion type based on "brain-gut interaction" theory［J］.Acta Univ Tradit Med Sin Pharmacol Shanghai，2022，36（5）：12-16.
  23. 23.
    WU S F，WANG W P，WEI Q Z.Clinical observation on modified Xinglou Chengqi decoction in the treatment of stroke-related pneumonia in patients in the department of critical care medicine［J］.Strait Pharm J，2014，26（11）：197-199.
  24. 24.
    GE C，KUANG J.Clinical effective observation on treating acute stroke constipation with the Xinglou Chengqi decoction［J］.Clin J Chin Med，2018，10（12）：27.
  25. 25.
    XIANG Y J.Observation on the efficacy of Xinglou Chengqi decoction in treating acute stroke and constipation［J］.Mod J Integr Tradit Chin West Med，2013，22（15）：1633-1634.
  26. 26.
    LIU J H.Clinical observation on the treatment of 31 cases of constipation of phlegm-heat-viscera solid type in the acute stage of stroke by adding flavour to Xinglou Chengqi decoction［J］.J New Chin Med，2011，43（7）：23-24.
  27. 27.
    SHEN B，YU C，XU Y P，et al.Clinical evaluation on two drug-delivery modes of treatment of reducing phlegm and obstruction-removing for constipation caused by acute cerebral infarction［J］.Chin J Mod Distance Educ Chin Med，2015，13（2）：37-39.
  28. 28.
    WANG S，CHEN P，JIANG L，et al.Therapeutic efficacy of Xinglou Chengqi decoction in treating constipation of phlegm-heat-viscera type in the acute stage of cerebral infarction［J］.Chin J Integr Med Cardio/Cerebrovasc Dis，2017，15（23）：3056-3058.
  29. 29.
    LONG T，ZENG X H.Clinical efficacy of Xinglou Chengqi decoction combined with ambroxol in the treatment of bedridden elderly with hypostatic pneumonia after stroke［J］.Neimonggu J Tradit Chin Med，2022，41（1）：35-36.
  30. 30.
    WANG N，SONG Y H，YANG Y J，et al.The effect of modified Xinglou Chengqi decoction combined with butylphthalide in the treatment of cognitive impairment after cerebral infarction and its influence on serum brain-gut peptide factor，homocysteine and β-amyloid protein 1-42 levels［J］.China Med，2024，19（12）：1851-1856.
  31. 31.
    JIANG X，CHEN S X，JI J.Effect of Xinglou Chengqi decoction on cognitive impairment in patients with cerebral ischemic stroke［J］.China Mod Doctor，2021，59（34）：136-139.
  32. 32.
    WANG X L.Clinical observation on treating cerebral apoplexy with pulmonary infection with the Xinglou Chengqi decoction［J］.Clin J Chin Med，2017，9（28）：92-93.
  33. 33.
    DENG Y.Effect of modified Xinglou Chengqi decoction in the treatment of patients in recovery period of stroke hemiplegia［J］.Clin Res Pract，2018，3（24）：92-93.
  34. 34.
    CHEN C，LI W，GENG H L，et al.Exploration on the action mechanism of Xinglou Chengqi decoction in the treatment of acute cerebral infarction based on network pharmacology［J］.World Chin Med，2021，16（21）：3161-3167.
  35. 35.
    ZENG P，ZHOU H.Homogenization of key components screening of "different diseases and different prescriptions" in network pharmacology［J］.Chin J Exp Tradit Med Form，2022，28（18）：177-191.
  36. 36.
    WANG P，WANG S，CHEN H，et al.TCMIP v2.0 powers the identification of chemical constituents available in Xinglou Chengqi decoction and the exploration of pharmacological mechanisms acting on stroke complicated with tanre fushi syndrome［J］.Front Pharmacol，2021，12：598200.
  37. 37.
    LI J H，YU Y，ZHANG Y J，et al.Flavonoids derived from Chinese medicine：Potential neuroprotective agents［J］.Am J Chin Med，2024，52（6）：1613-1640.
  38. 38.
    DAINA A，MICHIELIN O，ZOETE V.SwissADME：A free web tool to evaluate pharmacokinetics，drug-likeness and medicinal chemistry friendliness of small molecules［J］.Sci Rep，2017，7（1/4）：42717.
  39. 39.
    LIPINSKI C A，LOMBARDO F，DOMINY B W，et al.Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings［J］.Adv Drug Deliv Rev，2001，46（1-3）：3-26.
  40. 40.
    ZHOU Z K，ZHANG W J.Clinical observation on the treatment of acute ischemic stroke （phlegm-heat viscera syndrome） with sequential therapy of Chinese medicine［J］. J Emerg Tradit Chin Med，2023，32（10）：1767-1769.
  41. 41.
    BANERJEE P，ECKERT A O，SCHREY A K，et al.ProTox-II：A webserver for the prediction of toxicity of chemicals［J］.Nucleic Acids Res，2018，46（W1）：W257-W263.
  42. 42.
    WEI Z T，GAO Y L，MENG F，et al.iDMer：An integrative and mechanism-driven response system for identifying compound interventions for sudden virus outbreak［J］.Brief Bioinform，2021，22（2）：976-987.
  43. 43.
    LI S J.Adenosine：A procursor of ATP，with cytoprotective and cytotoxic effects［D］.Guangzhou：Guangzhou Medical University，2010.
  44. 44.
    ZHANG S C.Hypothesis and implication of brain-intestine connection［J］.Chin J Basic Med Tradit Chin Med，2002（6）：6-7.
  45. 45.
    REN G H，SUN Y L，QIN Y S.Research status of the relationship between stroke and brain-gut axis［J］.Guangming J Chin Med，2024，39（8）：1661-1664.
  46. 46.
    SUN Y，LIN Y J，WANG J H，et al.Risk factors for constipation in patients with acute and subacute ischemic stroke：A retrospective cohort study［J］.J Clin Neuro Sci，2022，106：91-95.
  47. 47.
    QIN Y Q，ZHANG Q P，YAO C Z，et al.Effect of Xinglou Chengqi decoction on quality of life of post-stroke constipation patients［J］.Clin J Tradit Chin Med，2019，31（10）：1974-1977.
  48. 48.
    ZHUANG J N.Progress of research on the main components of Rheum palmatum and its clinical pharmacology［J］.J Mil Surg Southwest China，2009，11（5）：931-933.
  49. 49.
    XI X M，BI H Y，CAO H H，et al.Review of traditional Chinese medicine rehabilitation model of parkinson's disease based on brain-gut axis theory［J］.Shandong J Tradit Chin Med，2022，41（1）：120-125.
  50. 50.
    HE J，FENG Y F，CHEN B，et al.Effect of raw rhubarb combined with mirabilite on patients with severe acute pancreatitis［J］.Chin J Pract Med，2018，45（18）：94-97.
  51. 51.
    GAO B W，DING Y，WANG X C.Effect of external application of mannite on the recovery of gastrointestinal function after laparoscopic appendectomy［J］.Clin Med，2024，44（3）：114-116.
  52. 52.
    TANG Z Q，LI B，WANG Q H，et al.Progress in the study of chemical composition，pharmacological effects and clinical application of related compound formulas of Arisaema Cum Bile［J］.China Pharm，2020，31（12）：1523-1527.
  53. 53.
    DASH S，CLARKE G，BERK M，et al.The gut microbiome and diet in psychiatry：Focus on depression［J］.Curr Opin Psychiatry，2015，28（1）：1-6.
  54. 54.
    PLUTA R，JANUSZEWSKI S，CZUCZWAR S J.The role of gut microbiota in an ischemic stroke［J］.Int J Mol Sci，2021，22（2）：915.
  55. 55.
    LI Q R，WANG C Y，TANG C，et al.Lymphocyte depletion after alemtuzumab induction disrupts intestinal fungal microbiota in Cynomolgus monkeys［J］.Transplantation，2014，98（9）：951-959.
  56. 56.
    WANG H Q，LIN S K，LEI X J，et al.Discussion on the role of Xingqi decoction in improving the intestinal microecology of acute cerebral infarction and its efficacy［J］.Chin Arch Tradit Chin Med，2025，43（10）：208-211.
  57. 57.
    ZHANG X X，WANG Y P，WANG Y F，et al.Effect of pericarpium trichosanthis on immune function of immunosuppressive mice induced by cyclophosphamide［J］.China Pharm，2009，20（9）：648-650.
  58. 58.
    LI B L，DU P L，DU Y，et al.Luteolin alleviates inflammation and modulates gut microbiota in ulcerative colitis rats［J］.Life Sci，2021，269：119008.
  59. 59.
    LARROSA M，YAÑÉZ-GASCÓN M J，SELMA M V，et al.Effect of a low dose of dietary resveratrol on colon microbiota，inflammation and tissue damage in a DSS-induced colitis rat model［J］.J Agric Food Chem，2009，57（6）：2211-2220.
  60. 60.
    JUNG C M，HEINZE T M，SCHNACKENBERG L K，et al.Interaction of dietary resveratrol with animal-associated bacteria［J］.FEMS Microbiol Lett，2009，297（2）：266-273.
  61. 61.
    QIAO Y，SUN J，XIA S F，et al.Effects of resveratrol on gut microbiota and fat storage in a mouse model with high-fat-induced obesity［J］.Food Funct，2014，5（6）：1241-1249.
  62. 62.
    ETXEBERRIA U，ARIAS N，BOQUÉ N，et al.Reshaping faecal gut microbiota composition by the intake of trans-resveratrol and quercetin in high-fat sucrose diet-fed rats［J］.J Nutr Biochem，2015，26（6）：651-660.
  63. 63.
    CHEN M L，YI L，ZHANG Y，et al.Resveratrol attenuates trimethylamine-N-oxide （TMAO）-induced atherosclerosis by regulating TMAO synthesis and bile acid metabolism via remodeling of the gut microbiota［J］.mBio，2016，7（2）：e02210-e02215.
  64. 64.
    ROST N S，BRODTMANN A，PASE M P，et al.Post-stroke cognitive impairment and dementia［J］.Circ Res，2022，130（8）：1252-1271.
  65. 65.
    SENNFÄLT S，PIHLSGÅRD M，PETERSSON J，et al.Long-term outcome after ischemic stroke in relation to comorbidity-an observational study from the Swedish Stroke Register （Riksstroke）［J］.Eur Stroke J，2020，5（1）：36-46.
  66. 66.
    CHEN G，HU X Z.Liver-brain-gut axis and traditional Chinese medicine syndrome differentiation of Zang-Fu organ［J］.J Sichuan Tradit Chin Med，2020，38（12）：26-28.
  67. 67.
    HE C F，MA C Y，LIU X Z.Mechanism of the Tongfu therapy for the treatment of ischemic stroke based on "brain-gut interaction"［J］.World Sci Technol Mod Tradit Chin Med，2024，26（3）：617-621.
  68. 68.
    FAN Q，ZHAO F，YU H M.Treatment of ischemic stroke based on "the six Fu-organs must keep their unobstructed"［J］.J Shanxi Univ Chin Med，2024，25（8）：928-933.
  69. 69.
    LUO Y，YAN B C，ZHANG L，et al.The new explanation of disturbance of consciousness of acute cerebral apoplexy with phlegm heat excess syndrome based on brain-gut axis［J］.J Emerg Tradit Chin Med，2020，29（7）：1219-1223.
  70. 70.
    ZHOU S B，LI J Z，LIU R，et al.Recent development of the flavonoids on the treatment of Alzheimer's disease［J］.Acta Neuropharmacol，2015，5（1）：51-58.
  71. 71.
    GUO Y，LI Q Y，YU X H，et al.Rhubarb anthraquinone glycosides protect against cerebral ischemia-reperfusion injury in rats by regulating brain-gut neurotransmitters［J］.Biomed Chromatogr，2021，35（5）：e5058.
  72. 72.
    LU T X，ROTHENBERG M E.MicroRNA［J］.J Allergy Clin Immunol，2018，141（4）：1202-1207.
  73. 73.
    ZHANG M，JIN Y L，GUO X R，et al.Resveratrol protects mesangial cells under high glucose by regulating the miR-1231/IGF1/ERK pathway［J］.Environ Toxicol，2024，39（4）：2326-2339.
  74. 74.
    FANG Y Y，SU Z H，SI W X，et al.Network pharmacology-based study of the therapeutic mechanism of resveratrol for Alzheimer's disease［J］.J South Med Univ，2021，41（1）：10-19.
  75. 75.
    AYERBE L，AYIS S，CRICHTON S L，et al.Explanatory factors for the increased mortality of stroke patients with depression［J］.Neurology，2014，83（22）：2007-2012.
  76. 76.
    LI W，LING S，YANG Y，et al.Systematic hypothesis for post-stroke depression caused inflammation and neurotransmission and resultant on possible treatments［J］.Neuro Endocrinol Lett，2014，35（2）：104-109.
  77. 77.
    LAI C F，QIU T，CHEN H Y，et al.Exploring the mechanism of rhubarb treatment of post-stroke depression based on brain-gut axis and network pharmacology［J］.Zhejiang J Integr Tradit Chin West Med，2023，33（3）：263-266.
  78. 78.
    ZHOU H W，ZHANG H S，ZHU H F，et al.Effects of emodin on depression-derived behavioral changes and brain monoamine neurotransmitters in rats［J］.Acta Med Univ Sci Technol Huazhong，2017，46（2）：150-154.
  79. 79.
    OWJFARD M，RAHIMIAN Z，KARIMI F，et al.A comprehensive review on the neuroprotective potential of resveratrol in ischemic stroke［J］.Heliyon，2024，10（14）：e34121.
  80. 80.
    LANGE K W，LI S M.Resveratrol，pterostilbene，and dementia［J］.Bio Factors，2018，44（1）：83-90.
  81. 81.
    ZHANG F，LIU J，SHI J S.Anti-inflammatory activities of resveratrol in the brain：Role of resveratrol in microglial activation［J］.Eur J Pharmacol，2010，636（1/3）：1-7.
  82. 82.
    MA C F，WANG Y，DONG L，et al.Anti-inflammatory effect of resveratrol through the suppression of NF-κB and JAK/STAT signaling pathways［J］.Acta Biochim Biophys Sin （Shanghai），2015，47（3）：207-213.
  83. 83.
    BAI Y J，SUI R B，ZHANG L，et al.Resveratrol improves cognitive function in post-stroke depression rats by repressing inflammatory reactions and oxidative stress via the Nrf2/HO-1 pathway［J］.Neuroscience，2024，541：50-63.
  84. 84.
    LIU D X，XIE K，YANG X D，et al.Resveratrol reverses the effects of chronic unpredictable mild stress on behavior，serum corticosterone levels and BDNF expression in rats［J］.Behav Brain Res，2014，264：9-16.
  85. 85.
    NEZHAD SALARI A M，RASOULIZADEH Z，SHABGAH A G，et al.Exploring the mechanisms of kaempferol in neuroprotection：Implications for neurological disorders［J］.Cell Biochem Funct，2024，42（2）：e3964.
  86. 86.
    ZHANG S，ZHANG Y，LI B，et al.Protective effects of kaempferol on autophagy- and oxidative stress-mediated injury of hippocampal neuron in CUMS-induced depression model rats［J］.Chin J Immunol，2019，35（2）：146-150.
  87. 87.
    SU P，LIU L M，GONG Y H，et al.Kaempferol improves depression-like behaviors through shifting microglia polarization and suppressing NLRP3 via tilting the balance of PPARγ and STAT1 signaling［J］.Int Immunopharmacol，2024，143（Pt 3）：113538.
  88. 88.
    SU P，LI Z B，YAN X L，et al.Quercetin and kaempferol inhibit HMC-1 activation via SOCE/NFATc2 signaling and suppress hippocampal mast cell activation in lipopolysaccharide-induced depressive mice［J］.Inflamm Res，2024，73（6）：945-960.
  89. 89.
    SONG P，ZHANG X，YAO H G.Characteristics of TCM symptoms and syndrome patterns in stroke associated pneumonia［J］.J Pract Med，2018，34（9）：1557-1560.
  90. 90.
    HUANG L，ZHANG Y J，LIAO R Y，et al.Meta-analysis of adjuvant therapy of TCM on stroke-associated pneumonia［J］. J Tradit Chin Med Univ Hunan，2016，36（1）：81-84.
  91. 91.
    ZHU W X，WU Y H，LI L Y，et al.Clinical effects of Xinglou Chengqi decoction on stroke associated pneumonia of phlegm heat and fu excess type［J］.J Shaanxi Coll Tradit Chin Med，2021，44（3）：97-101.
  92. 92.
    YAN F Q.Clinical study of Xinglou Chengqi decoction intreating stroke-associated pneumonia of heat-phlegmand sthenic-fu type［D］.Nanning：Guangxi University of Chinese Medicine，2020.
  93. 93.
    XIONG W Q.Analysis of the clinical effect of Xinglou Chengqi decoction in the treatment of ICU in patients with stroke associated pneumonia［J］.Chin Community Dr，2018，34（1）：93-95.
  94. 94.
    LI M，GAO C J.Research progress on the function of LFA-1 and ligand ICAM-1 adhesion molecules［J］.J Exp Hematol，2008（1）：213-216.
  95. 95.
    RUTA U，GERDING H，MÖLLHOFF T.Effect of locally applied lidocaine on expression of the oculocardiac reflex［J］.Ophthalmologe，1997，94（5）：354-359.
  96. 96.
    WANG M Y，CHEN T Y.A review on treating cough variant asthma in TCM medicine based on nuclear factor-κB signaling pathway［J］.Clin J Chin Med，2022，14（16）：117-120.
  97. 97.
    HU J P，WANG J，WU L，et al.The dynamic study on the influence of 3 Chinese herbal compound formula on the expression of ICAM-1 and NF-κB protein in cerebral tissue after focal cerebral ischemia-reperfusion in rats［J］.J Emerg Tradit Chin Med，2007，16（5）：571-573.
  98. 98.
    LI D M.Clinical study on the treatment of community-acquired pneumonia in patients with post-stroke sequelae by adding flavoured Xinglou Chengqi decoction［D］.Beijing：Beijing University of Chinese Medicine，2014.
  99. 99.
    GAO Y L，WANG W Z.Progress in the epidemiological study of cerebrovascular disease［J］.Chin J Neurol，2015，48（4）：337-340.
  100. 100.
    XIE M，ZHOU X X，CHEN W，et al.Clinical study of electronic moxibustion combined with rehabilitation training in the treatment of upper limb spastic hemiplegia in the convalescent stage of stroke［J］.Clin J Tradit Chin Med，2022，34（11）：2172-2176.
  101. 101.
    MA Y Z，WU J T.Effects of Xinglou Chengqi decoction on serum tumor necrosis factor and nitric oxide contents in the patient of acute cerebral infarction［J］.J Tradit Chin Med，2003，44（9）：674-675.
  102. 102.
    LIU J X，LI J S，YU W，et al.Effects of Xinglou Chengqi decoction and Buyang Huanwu decoction on the injury of hippocampal neurons in rats with cerebral ischemia［J］.Chin J Exp Tradit Med Form，2012，18（12）：233-237.
  103. 103.
    LUO Y Y.Therapeutic effect of Xinglou Chengqi decoction combined with eye acupuncture on treatment of hot and cold type of stroke［J］.Contemp Med，2020，26（9）：49-52.
  104. 104.
    QIN X J，WU H X，JIANG W.Influence of Xinglou Chengqi decoction on cerebral edema and metabolism of free radicals of experimental rat with cerebral hemorrhage［J］.Hebei J Tradit Chin Med，2005，27（5）：388-390.

Leer el texto completo

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website